Choose which categories of cookies you allow. Strictly necessary cookies are always on.
Required for core site functionality, security and your session. Always active.
Help us understand how visitors use the site (e.g. Google Analytics) so we can improve it.
Used to measure campaigns and show you relevant ads on other sites (e.g. LinkedIn, Google Ads).
Seasonal Influenza Vaccine Market Analysis size 2021 was recorded $1328.58 Million whereas by the end of 2026 it will reach $1889.94 Million. According to the author, by 2033 Seasonal Influenza Vaccine market size will become $3096.53 Million. Seasonal Influenza Vaccine market will be growing at a CAGR of 7.306% during 2026 to 2033. Download a free sample with data verified by Supriya Yadav
| Data Timeline | Historical Data: 2022–2025 | Base Year: 2025 | Forecast Period: 2026–2034 |
|---|---|
| Product Type Segment | Type A (H1N1), Type A (H3N2), Type B |
| Age Group Segment | Paediatrics, Adolescence, Adults, Elderly |
| Vaccine Type Segment | Quadrivalent, Trivalent, High-Dose |
|---|---|
| End-users Segment | Hospitals, Clinics, Ambulatory care centers |
| Regions & Countries |
|
Country-level data · Company profiles · Editable dataset · Analyst consultation included.
| Region / Country | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|---|---|---|---|
| Global | $ 1328.58 Million | $ 1761.5 Million | $ 3096.53 Million | 7.306% |
| North America | $ 684.22 Million | $ 895.72 Million | $ 1535.88 Million | 6.973% |
| United States | $ 548.74 Million | $ 715.32 Million | $ 1215.34 Million | 6.85% |
| Canada | $ 78 Million | $ 104.71 Million | $ 189.07 Million | 7.666% |
| Mexico | $ 57.47 Million | $ 75.69 Million | $ 131.47 Million | 7.146% |
| Europe | $ 216.56 Million | $ 278.32 Million | $ 467.58 Million | 6.7% |
| United Kingdom | $ 28.37 Million | $ 37.02 Million | $ 63.92 Million | 7.066% |
| France | $ 25.99 Million | $ 32.7 Million | $ 52.37 Million | 6.062% |
| Germany | $ 44.83 Million | $ 58.73 Million | $ 103.8 Million | 7.38% |
| Italy | $ 23.87 Million | $ 30.34 Million | $ 49.75 Million | 6.378% |
| Russia | $ 14.6 Million | $ 17.92 Million | $ 27.54 Million | 5.516% |
| Spain | $ 20.18 Million | $ 26.19 Million | $ 44.89 Million | 6.967% |
| Sweden | $ 14.55 Million | $ 18.84 Million | $ 32.05 Million | 6.866% |
| Denmark | $ 8.01 Million | $ 10.16 Million | $ 16.65 Million | 6.367% |
| Switzerland | $ 10.68 Million | $ 13.42 Million | $ 21.46 Million | 6.05% |
| Luxembourg | $ 2.38 Million | $ 2.94 Million | $ 4.51 Million | 5.504% |
| Rest of Europe | $ 23.11 Million | $ 30.07 Million | $ 50.64 Million | 6.732% |
| Asia Pacific | $ 233.83 Million | $ 325 Million | $ 628.6 Million | 8.595% |
| China | $ 65.01 Million | $ 91 Million | $ 178.84 Million | 8.812% |
| Japan | $ 39.52 Million | $ 53.79 Million | $ 99.07 Million | 7.933% |
| South Korea | $ 21.28 Million | $ 28.89 Million | $ 53.37 Million | 7.972% |
| India | $ 29.23 Million | $ 42.09 Million | $ 87.38 Million | 9.561% |
| Australia | $ 12.39 Million | $ 16.38 Million | $ 28.85 Million | 7.333% |
| Singapore | $ 7.72 Million | $ 10.92 Million | $ 21.69 Million | 8.955% |
| Taiwan | $ 10.06 Million | $ 13.68 Million | $ 25.62 Million | 8.157% |
| South East Asia | $ 24.08 Million | $ 34.09 Million | $ 68.08 Million | 9.029% |
| Rest of APAC | $ 24.55 Million | $ 34.16 Million | $ 65.71 Million | 8.523% |
| South America | $ 81.04 Million | $ 108.86 Million | $ 195.76 Million | 7.611% |
| Brazil | $ 29.42 Million | $ 39.3 Million | $ 69.93 Million | 7.469% |
| Argentina | $ 16.13 Million | $ 22.02 Million | $ 41.05 Million | 8.095% |
| Colombia | $ 11.83 Million | $ 15.87 Million | $ 27.42 Million | 7.076% |
| Peru | $ 5.51 Million | $ 7.35 Million | $ 12.98 Million | 7.37% |
| Chile | $ 7.38 Million | $ 9.98 Million | $ 18.27 Million | 7.844% |
| Rest of South America | $ 10.78 Million | $ 14.35 Million | $ 26.13 Million | 7.784% |
| Middle East | $ 58.46 Million | $ 78.3 Million | $ 139.87 Million | 7.522% |
| Saudi Arabia | $ 16.31 Million | $ 21.92 Million | $ 39.39 Million | 7.603% |
| Turkey | $ 9.82 Million | $ 13.3 Million | $ 24.44 Million | 7.897% |
| UAE | $ 10.7 Million | $ 14.63 Million | $ 27.33 Million | 8.121% |
| Egypt | $ 7.25 Million | $ 9.56 Million | $ 16.39 Million | 6.973% |
| Qatar | $ 6.08 Million | $ 8.06 Million | $ 14.14 Million | 7.285% |
| Rest of Middle East | $ 8.3 Million | $ 10.83 Million | $ 18.18 Million | 6.693% |
| Africa | $ 54.47 Million | $ 75.3 Million | $ 128.85 Million | 6.944% |
| East Africa | xxxx | xxxx | xxxx | xxxx |
| West Africa | xxxx | xxxx | xxxx | xxxx |
| North Africa | xxxx | xxxx | xxxx | xxxx |
| South Africa | $ 19.17 Million | $ 27.08 Million | $ 48.73 Million | 7.62% |
A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.
Unlock full regional dataset →Type A (h1n1) was the leading category of Seasonal Influenza Vaccine market category. The most common seasonal influenza is Type A (h1n1), and the market for type A seasonal influenza vaccine is on an exponential rise. Seasonal Influenza Vaccine Market, by Type Type A (H1N1) Type A (H3N2) Type B
Charts are illustrative — exact values, country-level breakdowns, and full forecast in the paid report. Request a Free Sample PDF.
To learn more about market share and segmentation, request the free sample pages.
In 2023,H3N2 VIRUS is a non-human influenza virus that normally circulates in pigs and that has infected humans. Influenza A (H3N3) is responsible for the present rise in flu cases as notified by ICMR. Both H1N1 and H3N2 sub-types are variants of influenza A which change genetically as well as antigenically to produce new variants. H3N2 tends to change more rapidly, both genetically and antigenically, compared to H1N1. H3N2 is the cause behind the rise in flu cases that we have been seeing recently.
In June 2023,Universal influenza vaccines are created to provide protection against more strains of the virus than quadrivalent influenza vaccines. The antibodies produced as a result of these universal influenza vaccinations should be able to recognize conserved epitopes on the surface of various influenza strains. This would be particularly advantageous in the event of an influenza pandemic arising from a new strain.
| Top Companies (In no particular order) | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| Sanofi | ••• | ••• | ••• | ••• |
| Merck & Co | ••• | ••• | ••• | ••• |
| Novartis | ••• | ••• | ••• | ••• |
| GlaxoSmithKline | ••• | ••• | ••• | ••• |
| Changsheng Bio-Technology Co. | ••• | ••• | ••• | ••• |
| Abbott Laboratories | ••• | ••• | ••• | ••• |
| Aleph Biomedical | ••• | ••• | ••• | ••• |
We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.
Request company profile for validation →The global seasonal influenza vaccine market is on a robust growth trajectory, projected to expand from $1,328.58 million in 2021 to $3,096.53 million by 2033, registering a compound annual growth rate (CAGR) of 7.306%. This expansion is primarily driven by heightened public awareness of infectious diseases, expanded government-led immunization programs, and the increasing prevalence of influenza, particularly among vulnerable populations. Technological advancements in vaccine production, such as the shift towards cell-based and recombinant vaccines, are also key contributors, offering faster production cycles and improved efficacy. North America currently dominates the market, but the Asia-Pacific region is poised to exhibit the fastest growth, fueled by rising healthcare expenditure and a large, underserved population. While the market presents significant opportunities, challenges such as vaccine hesitancy, complex manufacturing logistics, and the need for annual strain updates remain key considerations for stakeholders.
Manufacturers should prioritize investment in next-generation vaccine platforms like mRNA and universal flu vaccines to gain a long-term competitive edge. Expanding manufacturing capabilities in high-growth regions, particularly Asia-Pacific, can capitalize on emerging demand and mitigate supply chain risks. Forming strategic partnerships with government health agencies and NGOs is crucial for enhancing vaccine distribution networks and combating misinformation through unified public awareness campaigns. Furthermore, focusing on the development of high-dose or adjuvanted vaccines tailored for the elderly population can address a key high-risk demographic and secure market share.
Seasonal influenza vaccine is referred as the flu shot which is a vaccine indicated for the protection from the seasonal flu. The vaccine is given with a needle, usually in the arm to protect the person from Influenza. Influenza is a term used for the acute respiratory illness, commonly affect the upper and/or lower respiratory tract. The influenza is caused by the influenza virus which circulates in temperate regions and some tropical regions leading to the seasonal epidemics and year-round epidemics.
The influenza virus is potential to show various mutation and hence to better match the currently floating influenza strains, the manufacturers are advised to change the vaccine strains annually. The seasonal influenza vaccine is potent against the three or four influenza viruses which are most common in the upcoming season.
There are two types of influenza vaccine which are mostly available, inactivated influenza vaccines (IIV) and live attenuated influenza vaccines (LAIV) and these are indicated to administered annually to provide optimal protection against infection.
Normally the symptoms seen in the influenza patients are high fever, chills, body aches, sore throat, cough, fatigue etc. Most of the people recover in a few days or in less than 14 days, but in some people the complications such as pneumonia, ear infections, myocarditis, myositis, rhabdomyolysis etc. are develop which is life-threatening and may also lead to the death of patient. Hence the annual shots of influenza vaccine are recommended for the pediatric and geriatrics group and the people associated with the other disease conditions. In the northern hemisphere, annual influenza epidemics occur during autumn and winter affecting approximately 5-15% of the population.
Seasonal influenza vaccine is segmented into various main categories which includes Vaccine Type (Trivalent flu vaccines and Quadrivalent flu vaccines), by Virus Type (Influenza Virus Type A, Influenza Virus Type B), by Age Group (Pediatrics, Adults), by End User (Hospitals, Clinics, Ambulatory care centers) and by technology (egg-based, cell-culture based, recombinant).
The increasing awareness among the population, government involvement for the well-being its citizens, increasing investment in research and development activities by companies are few factors which are leading the growth of market and is expected to show the potential growth in the coming years.
As per Cognitive's Research Analyst, Seasonal Influenza Vaccine are integral for global public health, specifically designed to combat the annual influenza epidemics. They play an essential role in preventing severe illness, reducing healthcare burdens, and protecting vulnerable populations across various applications, including general public immunization and targeted high-risk groups.
Looking at the Historical Growth The global market expanded from $1,328.58 million in 2021 to an estimated $1889.94 million in 2026 due to heightened public awareness of infectious diseases, expanded government-led immunization programs, and the increasing prevalence of influenza. Regionally, North America grew from $684.217 million in 2021 to $958.12 million in 2026, while Asia Pacific progressed from $233.829 million to $352.93 million over the same period.
Currently in 2026, North America holds a commanding 50.70% of the global market, driven by high vaccination rates, strong government support, and the presence of major pharmaceutical manufacturers. Additionally Asia Pacific is set to be the fastest-growing region, exhibiting the highest CAGR of 8.595%, fueled by increasing healthcare awareness, government initiatives, and a large population base.
The market is witnessing a definitive shift towards advanced vaccine technologies, including quadrivalent, cell-based, and recombinant vaccines, driven by the demand for broader protection and more reliable manufacturing processes. Ongoing innovation in next-generation vaccine platforms like mRNA is also leading, focusing on developing universal influenza vaccines that provide long-lasting protection.
In the future, The global Seasonal Influenza Vaccine market will reach to $3,096.53 million by 2033, expanding at a compound annual growth rate of 7.306% from 2021, primarily driven by the amplified importance of widespread vaccination and consistent demand from annual influenza outbreaks. Ongoing advancements in vaccine technology and the strong trend towards achieving broader and more durable protection will also contribute significantly.
Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.
Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.
In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.
Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.
★ Reviews
Rate this report
| Product Type | Type A (H1N1), Type A (H3N2), Type B |
|---|---|
| Age Group | Paediatrics, Adolescence, Adults, Elderly |
| Vaccine Type | Quadrivalent, Trivalent, High-Dose |
| End-users | Hospitals, Clinics, Ambulatory care centers |
| List of Competitors | Sanofi, Merck & Co, Novartis, GlaxoSmithKline, Changsheng Bio-Technology Co., Abbott Laboratories, Aleph Biomedical |
Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Seasonal Influenza Vaccine Market Analysis Market analysis.
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
Seasonal influenza vaccine is referred as the flu shot which is a vaccine indicated for the protection from the seasonal flu. The seasonal influenza vaccine is potent against the three or four influenza viruses which are most common in the upcoming season.
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Seasonal Influenza Vaccine Market Analysis market.
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the seasonal influenza vaccine market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
